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http:WHAT THIS PAPER ADDS
Angiosome-based revascularization is now widely used as a reliable strategy for surgical and endovascular
reconstruction in patients with CLI, yielding better clinical success including limb preservation and wound
healing. However, in the clinical setting, direct EVT, that is endovascular reconstruction for ischemic wounds
through their speciﬁc source artery, is not always successful because of technical barriers and lesion severity.
Because it remains unclear which patients derive the most clinical beneﬁt from direct EVT, our study’s main
objective was to investigate which patients with CLI would derive the most clinical beneﬁt from direct EVT. From
our results, indirect endovascular reconstruction is a clinically acceptable strategy for most patients with CLI due
to isolated infrapopliteal lesion. However, when the patient clinical status is complicated by the presence of
wound infection and diabetes, an effort should be made to accomplish direct endovascular reconstruction.Objectives: To investigate factors in patients with critical limb ischemia (CLI) and isolated infrapopliteal lesions
that adversely affect outcomes of endovascular therapy (EVT) with or without angiosome-oriented
revascularization.
Methods: This was a retrospective multicenter study. We used a database of 718 consecutive CLI patients
(70  11 years, 75% diabetics, 68% on hemodialysis, 24% Rutherford class 6) with ischemic tissue loss due to
isolated infrapopliteal lesions undergoing primary EVT. Primary outcome was MALE (major adverse limb event).
Association between indirect EVT (recanalization of a non-angiosome-based artery) and outcome was assessed
by Cox proportional hazard regression model.
Results: C-reactive protein (CRP) level was >3 mg/dL in 32% of cases. Indirect EVT (in 307 CLI patients, 43%), was
associated with MALE (p ¼ .04, hazard ratio [95% conﬁdence interval] 1.25 [1.01, 1.55]), and interacted with CRP
>3 mg/dL (p < .004) but not with other baseline characteristics. Indirect EVT with CRP >3 mg/dL had higher
MALE risk (HR 2.08), and interacted with diabetes mellitus (DM) presence. Indirect EVT with CRP >3 mg/dL and
DM had higher MALE risk (HR 2.17).
Conclusion: Limb prognosis was equivalent for direct and indirect endovascular revascularization except in the
presence of both diabetes and wound infection, when indirect revascularization has a poorer outcome.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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There is general agreement that patients with critical limb
ischemia (CLI) are optimally treated with revasculariza-
tion.1,2 In particular, angiosome-based revascularization is
touted as a reliable strategy for surgical and endovascular
576 O. Iida et al.reconstruction in patients with CLI, yielding better clinical
success including limb preservation and wound healing.3e6
However, in the clinical setting, direct EVT, that is endo-
vascular reconstruction for ischemic wounds through their
speciﬁc source artery, is not always successful because of
technical barriers and lesion severity, and approximately
40e50% of patients in earlier studies have been treated
with indirect EVT, with moderate limb preservation rates.5,6
Patients with CLI, especially those with diabetes mellitus
(DM) and end-stage renal disease (ESRD) on dialysis,
commonly present culprit lesions in the infrapopliteal re-
gion with long, diffuse arteriosclerotic disease.7,8 According
to the latest American College of Cardiology Foundation/
American Heart Association and European Society of Car-
diology Guidelines on the management of peripheral artery
diseases, primary angioplasty for infrapopliteal lesions is
recommended with a class IIa evidence level.9,10 This study
investigated factors in patients with CLI and isolated infra-
popliteal lesions that adversely affect outcomes of EVT with
direct or indirect revascularization.METHODS
Patients
The analysis for the current study was based on data
extracted from a multicenter database of 718 consecutive
CLI patients with ischemic tissue loss (i.e. Rutherford class 5
or class 6) due to isolated infrapopliteal lesions; details on
the creation of the study database and on the study pop-
ulation have been previously described.11 No patient had
aorto-iliac or femoropopliteal lesions, and all underwentTable 1. Baseline characteristics of the study population.
Overall (n ¼ 718) I
Age (year) 71  11 7
Male sex 501 (70) 2
Non-ambulatory status 331 (46) 1
Serum albumin (g/dL) 3.4  0.6 3
Diabetes mellitus 538 (75) 2
Hypertension 517 (72) 2
Hyperlipidemia 204 (28) 8
Smoking 250 (35) 1
Chronic renal failure (Cr >2 mg/dL) 486 (68) 2
Coronary artery disease 381 (53) 1
Cerebrovascular disease 180 (25) 7
Rutherford class 6 173 (24) 9
CRP 3 mg/dL 230 (32) 1
Three-vessel below-the-knee disease 472 (66) 2
Treated artery
Anterior tibial artery 502 (70) 1
Posterior tibial artery 351 (49) 1
Peroneal artery 276 (38) 1
Dorsalis pedis artery 107 (15) 3
Plantar artery 82 (11) 3
Arterial calciﬁcation 488 (68) 2
No below-the ankle runoff 171 (23) 8
Indirect EVT 307 (43)
Note. Data are represented as mean  SD or n (%). Value for p are be
reactive protein; EVT ¼ endovascular therapy.primary EVT with at least one vessel run-off to the ankle
successfully obtained. To assess the prognostic difference
between indirect and direct EVT, we excluded patients with
only one-vessel disease because these cases always entail
direct EVT, that is the diseased vessel is always the
angiosome-based artery. The study protocol was developed
in accordance with the Declaration of Helsinki, and
approved by the ethics committee of each participating
hospital. This study was registered in the University Hospital
Medical Information Network Clinical Trial Registry (UMIN-
CTR), which was approved by the International Committee
of Medical Journal Editors (no. UMIN000007016, J-BEAT II
registry: Japanese BElow-the-knee Artery Treatment registry
II). All patients gave written informed consent prior to
revascularization.
Study protocol
The deﬁnitions and methodology used in the creation of the
database have also been reported previously.11 Brieﬂy,
ankleebrachial index (ABI) and skin perfusion pressure
(SPP) were used to asses lower limb hemodynamics. Infra-
popliteal arterial lesions were routinely evaluated by duplex
ultrasound, and before revascularization by digital subtrac-
tion angiography (DSA). A group of vascular specialists
including vascular surgeons and radiologists judged whether
EVT was indicated for each patient. All endovascular pro-
cedures were performed under local anesthesia. EVT was
indicated when the lesion showed >75% diameter stenosis
on diagnostic angiography and was hemodynamically sig-
niﬁcant. Selection of the procedural approach was left to
the operator’s discretion. An antegrade approach with a 4Frndirect EVT (n ¼ 307) Direct EVT (n ¼ 411) p Value
1  11 71  10 .408
08 (68) 293 (71) .325
57 (51) 174 (42) .023
.4  0.6 3.5  0.6 .008
34 (76) 304 (74) .543
23 (73) 294 (72) .801
6 (28) 118 (29) .867
03 (34) 147 (36) .580
03 (66) 283 (69) .468
61 (52) 220 (54) .821
6 (25) 104 (25) .931
1 (30) 82 (20) .004
16 (38) 114 (28) .005
26 (74) 246 (60) <.001
71 (56) 331 (81) <.001
24 (40) 227 (55) <.001
40 (46) 136 (33 .001
5 (11) 72 (18) .026
5 (11) 47 (11) 1.000
06 (67) 282 (69) .687
5 (28) 86 (21) .042
e e e
tween the indirect EVT group and the direct EVT group. CRP ¼ C-
Figure 1. Prognostic impact of indirect endovascular therapy (EVT).
The rate of freedom from major adverse limb event (MALE) was
estimated by the KaplaneMeier method. Patients undergoing in-
direct EVT (dotted line, n ¼ 307) had a poorer prognosis than
those undergoing direct EVT (solid line, n ¼ 411) (p ¼ .041 by log
rank test).
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most preferably used. After inserting the sheath, unfrac-
tionated heparin (5,000 U) was routinely injected into the
artery. A 0.014-inch guidewire was advanced into the culprit
lesion and an optimally sized balloon catheter was intro-
duced. A 100- or 120-mm-long balloon (Shiden, Kaneka
Medix Corporation, Osaka, Japan; or Amphillion, Medtronic,
Minneapolis, MN, USA) was commonly used and balloon
inﬂation was held at nominal pressure for at least 180Table 2. Inﬂuence of covariates on the prognostic impact of indirect e
Covariate Unadjusted hazard ratio of in
Yes (with covariate)
Age 80 years 1.17 (0.66, 2.09)
Male sex 1.40 (1.08, 1.83)
Non-ambulatory status 1.20 (0.88, 1.63)
Serum albumin <3 g/dL 1.86 (1.12, 3.08)
Diabetes mellitus 1.34 (1.05, 1.72)
Hypertension 1.16 (0.89, 1.50)
Hyperlipidemia 1.18 (0.78, 1.78)
Smoking 1.11 (0.78, 1.58)
Chronic renal failure (Cr >2 mg/dL) 1.34 (1.04, 1.72)
Coronary artery disease 1.15 (0.86, 1.53)
Cerebrovascular disease 1.65 (1.06, 2.57)
Rutherford class 6 1.39 (0.94, 2.05)
CRP 3 mg/dL 1.84 (1.28, 2.66)
Three-vessel below-the-knee disease 1.31 (0.90, 1.90)
Arterial calciﬁcation 1.27 (0.99, 1.65)
No below-the-ankle runoff 0.97 (0.65, 1.45)
Overall 1.25 (1.01, 1.55)
Note. Data are unadjusted HR and 95% CI of indirect EVT for MALE in t
the interaction effect of each covariate with indirect EVT. CRP ¼ C-reac
limb event.seconds to avoid ﬂow-limiting dissection. Target lesion was
chosen based on lesion and limb severity and on the
angiosome concept. Dual antiplatelet therapy (aspirin at
100 mg/day and ticlopidine at 200 mg/day or cilostazol at
200 mg/day) was started at least 1 week prior to EVT and
continued lifelong. Antibiotics were routinely administered
if the ulcer was complicated with a limb-threatening severe
infection as judged by a plastic surgeon who evaluated and
managed the ulcer using the TIME concept.12
Study outcomes
As detailed in an earlier study, the primary outcome mea-
sure was MALE (major adverse limb events) deﬁned as
major amputation or any reintervention including repeat
angioplasty and surgical conversion.13
Follow-up protocol
At 1, 3, 6, and 12 months after EVT, each patient was
routinely assessed for ischemic symptoms, ABI, SPP (Sen-
silase PAD 3000, Väsamed, Eden Prairie, MN, USA), and
duplex ultrasound. Reintervention was conducted only
when indicated clinically by breakdown or delayed healing
of the primary ulcer.
Deﬁnitions
The deﬁnitions of lower limb severity and the criteria for
diagnosis of atherosclerosis risk factors have been reported
previously.11 In this study, chronic renal failure was deﬁned
as Cr level >2 mg/dL. Critical ischemic limb was deﬁned
according to the Trans-Atlantic Inter-Society Consensus II
guideline. When deﬁnition-required measurements could
not be obtained due to intractable rest pain or a non-
compressible artery with severe calciﬁcation, the SPP wasndovascular therapy EVT.
direct EVT for MALE in each subgroup p Value for interaction
No (without covariate)
1.31 (1.04, 1.65) .701
0.95 (0.65, 1.38) .087
1.26 (0.93, 1.71) .781
1.14 (0.90, 1.45) .084
1.00 (0.65, 1.54) .209
1.56 (1.05, 2.30) .251
1.29 (1.00, 1.66) .829
1.35 (1.03, 1.77) .401
1.24 (0.81, 1.90) .820
1.41 (1.01, 1.95) .346
1.13 (0.88, 1.45) .121
1.10 (0.84, 1.43) .223
0.96 (0.73, 1.27) .004
1.25 (0.96, 1.63) .802
1.25 (0.84, 1.86) .984
1.35 (1.04, 1.74) .169
e
he subgroups with and without each covariate. Values for p are for
tive protein; EVT ¼ endovascular therapy; MALE ¼ major adverse
578 O. Iida et al.measured instead of pressure at toe or ankle; an SPP
<40 mmHg was deﬁned as indicating a critical ischemic
limb. Coronary artery disease (CAD) and cerebrovascular
disease (CVD) were deﬁned as the presence of symptom or
past history of infarction or history of any intervention. BA
(below-the-ankle) disease was deﬁned as the presence of a
diseased arterial lesion at the dorsalis pedis or plantar ar-
tery. EVT procedural success was deﬁned as obtaining one
straight-line ﬂow to the foot without occurrence of any
ﬂow-limiting dissection. The treated lesion with the widest
limb perfusion area based on the angiosome concept was
identiﬁed as the target lesion in this study. EVT was deﬁned
as indirect when the limb had to be revascularized via a
non-angiosome-based artery. Direct EVT was deﬁned as
successful wound therapy by direct ﬂow achievement based
on the angiosome concept. Reintervention including repeat
angioplasty or bypass graft procedures was indicated for
limbs with recurrent symptoms accompanied by recurrent
stenosis >50% as measured by duplex ultrasound or DSA.
MALE was deﬁned as major amputation or any reinter-
vention during the study period. Any reintervention
included repeat angioplasty, new bypass graft, jump, or
interposition graft revision. Major amputation was deﬁned
as above-ankle amputation of the index limb. These deﬁ-
nitions were proposed by the Society of Vascular Surgery
(SVS).14Figure 2. Prognostic impact of indirect endovascular therapy (EVT)
and elevated C-reactive protein (CRP) levels. The study population
was stratiﬁed into four groups according to indirect/direct EVT and
CRP levels. The rate of freedom from major adverse limb event
(MALE) in each subgroup was estimated by the KaplaneMeier
method. Compared to patients undergoing direct EVT for critical
limb ischemia (CLI) with CRP <3 mg/dL (blue solid line, n ¼ 297),
patients undergoing indirect EVT for CLI with CRP 3 mg/dL (red
dotted line, n ¼ 114) had an increased risk for MALE (p < .001 by
the log rank test). On the other hand, the patients undergoing
indirect EVT for CLI with CRP <3 mg/dL (red solid line, n ¼ 116)
and the patients undergoing direct EVT for CLI with 3 mg/dL
(blue dotted line, n ¼ 191) had a similar risk for MALE, compared
to the reference subgroup (blue solid line) (p ¼ .467 and 0.789,
respectively).Statistical analysis
Data are shown as mean and standard deviation (SD) for
continuous variables or as a percentage for dichotomous
variables, unless otherwise mentioned. Between-group
differences were evaluated by the unpaired t test and the
Fisher exact test for continuous and dichotomous variables,
respectively. MALE rate was estimated by the Kaplane
Meier method and the difference among groups was
assessed by the log rank test. Association between revas-
cularization modality with outcome was assessed by Cox
proportional regression model. Hazard ratios (HR) are re-
ported with their 95% conﬁdence intervals (CI). The inﬂu-
ence of baseline characteristics on the association between
angiosome-based revascularization and outcome was eval-
uated by interaction effects. A p value <.05 was considered
statistically signiﬁcant. Statistical analyses were performed
using IBM SPSS Statistics Version 19 (SPSS Inc., Chicago, IL,
USA).
RESULTS
Baseline characteristics are shown in Table 1. Mean age was
70  11 years and 501 patients (70%) were male. The
prevalence of DM and chronic renal failure was 75%
(n ¼ 538) and 68% (n ¼ 486), respectively. A total of 307
patients (43%) underwent indirect EVT. Compared with the
direct EVT group, the indirect EVT group had a higher
prevalence of non-ambulatory status (51% vs. 42%;
p ¼ .023), lower mean serum albumin level (3.4  0.6 g/dL
vs. 3.5  0.6 g/dL; p ¼ .008), and a higher prevalence of
Rutherford class 6 (30% vs. 20%; p ¼ .004), elevated C-reactive protein (CRP) levels (3 mg/dL) (38% vs. 28%;
p ¼ .005), three-vessel below-the-knee disease (74% vs.
60%; p < .001), and absence of below-the ankle runoff (28%
vs. 21%; p ¼ .042). The median and interquartile range of
follow-up was 5 (2e15) months, during which MALE was
observed in 340 cases (47%).
Prognosis of indirect EVT
As shown in Fig. 1, the indirect EVT group had higher MALE
risk than the direct EVT group (p ¼ .041 by the log-rank
test; unadjusted HR and 95% CI of indirect EVT 1.25 [1.01,
1.55]). As shown in Table 2, indirect EVT had a signiﬁcant
interaction with CRP levels (p ¼ .004), but not with other
baseline characteristics (p > .05), suggesting a differential
prognostic impact of indirect EVT among groups stratiﬁed
by CRP levels. Indeed, the unadjusted HR of indirect EVT for
European Journal of Vascular and Endovascular Surgery Volume 46 Issue 5 p. 575e582 November/2013 579MALE was 1.84 (1.28, 2.66) in patients with high CRP levels
(3 mg/dL), and 0.96 (0.73, 1.27) in those with low CRP
levels (<3 mg/dL).
Fig. 2 shows the MALE rate in each of four subgroups
according to indirect/direct EVT and CRP ( or <3) levels.
Interestingly, the MALE risk was higher only in the subgroup
with indirect EVT and high CRP levels (HR 2.08 [1.56, 2.78],
p < .001). There was no signiﬁcant interaction effect with
hemodialysis.Prognostic impact of indirect EVT and elevated C-reactive
protein
The unadjusted HR for combined indirect EVT and high CRP
levels was 2.06 (1.58, 2.69) (p < .001), which is larger than
that of indirect EVT alone, that is 1.25 (1.01, 1.55).
As shown in Table 3, DM (p ¼ .021), but not the other
baseline characteristics (p > .05), had a signiﬁcant inter-
action effect with the combined indirect EVT and high CRP
levels. Indeed, the unadjusted HR of combined indirect EVT
and CRP levels 3 mg/dL for MALE was 2.43 (1.81, 3.27) in
diabetics, and 1.07 (0.55, 2.07) in non-diabetics.
As shown in Fig. 3, MALE risk was higher only in diabetics
who had undergone indirect EVT and had high CRP levels
(HR of 2.17 [1.54, 3.06] for MALE, compared to non-
diabetics who underwent direct EVT and/or had low CRP
levels, p < .001). These ﬁndings suggest that indirect EVT
for CLI with CRP 3 mg/dL increased MALE risk only in
diabetics.Prognosis of combined indirect EVT, elevated C-reactive
protein, and diabetes mellitus
The unadjusted HR of combined indirect EVT, high CRP level,
and DM for MALE was 2.37 [1.79, 3.15] (p < .001). No
covariate had an interaction effect with the latterTable 3. Inﬂuence of covariates on the prognostic impact of indirect E
Covariate Unadjusted hazard ratio
CRP 3 mg/dL” for MAL
Yes (with covariate)
Age 80 years 1.27 (0.50, 3.20)
Male sex 2.17 (1.56, 3.02)
Non-ambulatory status 1.90 (1.34, 2.70)
Serum albumin <3 g/dL 2.71 (1.62, 4.52)
Diabetes mellitus 2.43 (1.81, 3.27)
Hypertension 2.11 (1.54, 2.89)
Hyperlipidemia 1.87 (1.13, 3.11)
Smoking 2.37 (1.54, 3.64)
Chronic renal failure (Cr >2 mg/dL) 2.21 (1.63, 3.02)
Coronary artery disease 2.02 (1.42, 2.87)
Cerebrovascular disease 1.88 (1.05, 3.37)
Rutherford class 6 1.86 (1.24, 2.81)
Three-vessel below-the-knee disease 2.07 (1.29, 3.33)
Arterial calciﬁcation 2.26 (1.66, 3.07)
No below-the-ankle runoff 1.80 (1.17, 2.78)
Overall 2.06 (1.58, 2.69)
Note. Data are unadjusted HR and 95% CI of the coexistence of indir
without each covariate. Values for p values are the interaction effect
3 mg/dL. CRP ¼ C-reactive protein; EVT ¼ endovascular therapy; Mcombination (Table 4). As shown in Table 5, by Cox pro-
portional analysis: 1) age 80 years, 2) chronic renal failure
deﬁned as CR level >2 mg/dL, 3) Rutherford 6, 4) no below-
the-ankle run-off, and 5) indirect EVT for CLI with high CRP
level and DM independently impacted MALE. The latter
combination of the three variables had a signiﬁcant asso-
ciation with MALE, independently of other covariates
(adjusted HR for MALE of 1.80 [1.34, 2.42], p < .001).
Findings were similar to those when the study population
was limited to either patients on or not on hemodialysis
(Supplemental Tables 1e3). There was no interaction effect
of hemodialysis on the current ﬁndings.DISCUSSION
A total of 307 patients (43%) underwent indirect EVT in this
study. By univariate analysis, the indirect EVT group had a
higher risk for MALE than the direct EVT group. Indirect EVT
increased risk for MALE only in patients with high CRP level
(3 mg/dL) and DM. In terms of interaction effects of
clinical factors, indirect EVT with high CRP levels increased
MALE risk only in diabetics (HR 2.37). To the best of our
knowledge, this is the ﬁrst study to assess risk stratiﬁcation
of angiosome-based EVT in patients with CLI due to pure
isolated infrapopliteal lesions.
Patients with CLI, especially those with DM and ESRD on
dialysis who are common in contemporary clinical practice,
are still considered best treated with saphenous vein graft
bypass surgery as ﬁrst-line therapy.2 However, these pa-
tients are often not suitable surgical candidates due to
concomitant disease and advanced age, making EVT pref-
erable.15e17 Recently, EVT with traditional angioplasty is
most widely used in the infrapopliteal region because it
achieves acceptable limb preservation when compared with
bypass surgery.15e17VT for CLI with elevated C-reactive protein levels.
of “indirect EVT for CLI with
E in each subgroup
p Value for interaction
No (without covariate)
2.11 (1.59, 2.79) .318
1.77 (1.13, 2.79) .452
2.16 (1.42, 3.29) .735
1.81 (1.30, 2.51) .124
1.07 (0.55, 2.07) .021
2.05 (1.25, 3.36) .900
2.25 (1.65, 3.09) .585
1.92 (1.37, 2.70) .505
1.95 (1.15, 3.33) .740
2.18 (1.45, 3.29) .691
2.09 (1.55, 2.81) .731
1.59 (1.09, 2.31) .270
2.09 (1.51, 2.88) .915
1.64 (0.94, 2.85) .323
2.11 (1.49, 2.98) .681
e
ect EVT and CRP 3 mg/dL for MALE in the subgroups with and
of each covariate with the coexistence of indirect EVT and CRP
ALE ¼ major adverse limb event.
Figure 3. Prognostic impact of the coexistence of indirect endo-
vascular therapy (EVT) and elevated C-reactive protein (CRP) levels
and the presence of diabetes mellitus. The study population was
stratiﬁed into four groups according to the coexistence of indirect
EVT and elevated CRP levels (3 mg/dL) and the presence of
diabetes mellitus. The rate of freedom from major adverse limb
event (MALE) in each subgroup was estimated by the Kaplane
Meier method. Compared to the non-diabetic patients without the
coexistence of indirect EVT and CRP levels 3 mg/dL (i.e. the non-
diabetic patients who underwent direct EVT and/or had CRP levels
<3 mg/dL) (blue solid line, n ¼ 159), the diabetic patients with the
coexistence of indirect EVT and CRP 3 mg/dL (red dotted line,
n ¼ 95) had an increased risk for MALE (p < .001 by the log rank
test). On the other hand, the diabetic patients without the coex-
istence (red solid line, n ¼ 21) and the non-diabetic patients with
the coexistence (blue dotted line, n ¼ 443) had a similar risk for
MALE, compared to the reference subgroup (blue solid line)
(p ¼ .844 and 0.334, respectively).
580 O. Iida et al.Although angiosome-oriented revascularization is gener-
ally accepted in current surgical or endovascular practice, in
contemporary endovascular practice, wound territorial ar-
teries commonly appear to be affected by vast atheroscle-
rotic disease, and target arterial lesions based on the
angiosome concept are generally affected by more severe
arterial disease than other crural lesions which translates
into greater clinical challenge when using endovascular
reconstruction. Also, durability after traditional angioplasty
for infrapopliteal lesions is extremely poor, with general
health status impacting the wound-healing process.18
Inadequate perfusion is mainly secondary to suboptimal
acute results for surgical reconstruction and to a high inci-
dence of restenosis during the early phase after infrapo-
pliteal angioplasty. Therefore, the strategy for angiosome-based EVT should be decided based upon severity of
ischemic wounds and diseased artery.13 In this study, indi-
rect EVT increased risk for MALE only in patients with high
CRP level which most likely implied the presence of wound
infection. It is widely reported that the presence of wound
infection increases the demand for blood ﬂow to the
microvascular bed and consequently results in a higher
major amputation rate.1,2 To overcome infection, sufﬁcient
blood ﬂow, mainly rendered possible by direct endovascular
revascularization, would be mandatory to achieve freedom
from MALE. On the other hand, in this study the prognostic
impact of indirect EVT was not signiﬁcantly inﬂuenced by
wound severity, as assessed by the Rutherford classiﬁcation.
It might be that Rutherford class 6 itself had a strong as-
sociation with poor limb prognosis, which would leave little
room for interaction with indirect EVT.
The current study also revealed a signiﬁcant interaction
effect between indirect EVT for CLI with high CRP levels and
DM. DM appeared to be associated with poor limb prog-
nosis only when indirect EVT was performed for ischemic
tissue loss complicated with infection. Previous studies have
demonstrated that DM presence was independently asso-
ciated with poor limb prognosis.19 One possible explanation
for its signiﬁcant inﬂuence might be that DM reduces blood
ﬂow to the microvascular bed via an arteriovenous ﬁstula.
As described above, ischemic tissue loss with infection
would require sufﬁciently abundant blood ﬂow. The pres-
ence of DM might interfere with blood ﬂow, which might
lead to poor limb prognosis in the population. Furthermore,
a weakened immune response in diabetics might affect limb
prognosis in CLI complicated with infection.Limitations
There were several limitations to this study. First, this was a
retrospective and non-randomized study, despite use of a
prospectively maintained database with a large number of
consecutive CLI patients with pure isolated infrapopliteal
lesions. Additionally, results were not based on intention-
to-treat analysis because of inability to determine cross-
over magnitude. Given the baseline differences between
the indirect and direct EVT groups, propensity-matched
analysis appears better suited to adjust for baseline differ-
ences in direct comparisons, and further study is warranted.
Second, each CLI patient had various affected angiosomes.
In this study, however, all patients underwent DSA assess-
ment to elucidate the relationship between wounds and
their related artery. The presence of pedal arch, which im-
pacts limb prognosis, was not assessed. Third, the actual
number of patients with completely healed wounds, time to
wound healing, and all details of ulcer severity, especially
wound size and depth, were not evaluated among groups
because of the retrospective nature of the study. Addi-
tionally in this study, a high CRP level assessed by laboratory
examination was regarded as indicative of the presence of
wound infection instead of magnetic resonance imaging or
X-ray, which is commonly used as standard methodology for
assessment of osteomyelitis.
Table 4. Inﬂuence of covariates on the prognostic impact of indirect EVT for CLI with elevated C-reactive protein levels and diabetes
mellitus.
Covariate Unadjusted hazard ratio of “indirect EVT for CLI with CRP 3 mg/dL
and diabetes mellitus” for MALE in each subgroup
p Value for interaction
Yes (with covariate) No (without covariate)
Age 80 years 2.09 (.82, 5.32) 2.31 (1.72, 3.12) .817
Male sex 2.42 (1.71, 3.42) 2.15 (1.31, 3.54) .660
Non-ambulatory status 2.15 (1.49, 3.12) 2.57 (1.64, 4.04) .673
Serum albumin <3 g/dL 2.92 (1.70, 5.02) 2.10 (1.49, 2.96) .141
Hypertension 2.47 (1.77, 3.43) 2.19 (1.26, 3.81) .680
Hyperlipidemia 2.16 (1.27, 3.67) 2.57 (1.84, 3.60) .695
Smoking 2.11 (1.34, 3.32) 2.54 (1.77, 3.64) .494
Chronic renal failure (Cr >2 mg/dL) 2.38 (1.72, 3.29) 2.26 (1.25, 4.08) .964
Coronary artery disease 2.13 (1.48, 3.09) 2.79 (1.79, 4.35) .280
Cerebrovascular disease 2.12 (1.11, 4.03) 2.42 (1.76, 3.32) .673
Rutherford class 6 1.70 (1.12, 2.59) 2.00 (1.33, 3.00) .982
Three-vessel below-the-knee disease 2.29 (1.41, 3.71) 2.41 (1.70, 3.42) .946
Article calciﬁcation 2.46 (1.79, 3.38) 2.06 (1.07, 3.97) .633
No below-the-ankle runoff 2.27 (1.45, 3.57) 2.22 (1.52, 3.22) .712
Overall 2.37 (1.79, 3.15) e
Note. Data are unadjusted HR and 95% CI of the coexistence of indirect EVT, CRP 3 mg/dL, and diabetes mellitus for MALE in the
subgroups with and without each covariate. Values for p are the interaction effect of each covariate with the coexistence of indirect
EVT, CRP 3 mg/dL, and diabetes mellitus. CRP ¼ C-reactive protein; EVT ¼ endovascular therapy; MALE ¼ major adverse limb event.
Table 5. Risk factors for MALE.
Unadjusted HR in univariate
model




Indirect EVT for CLI with CRP 3 mg/dL and
diabetes mellitus
2.37 (1.79, 3.15)** 1.71 (1.26, 2.33)** 1.80 (1.34, 2.42)**
Age 80 years 0.60 (0.44, 0.82)** 0.67 (0.48, 0.93)* 0.69 (0.50, 0.94)*
Male sex 0.96 (0.77, 1.21) 0.78 (0.60, 1.00) e
Non-ambulatory status 1.24 (1.00, 1.54)* 1.07 (0.85, 1.36) e
Serum albumin <3 g/dL 1.23 (0.94, 1.62) 1.16 (0.87, 1.55) e
Hypertension 0.85 (0.68, 1.08) 0.88 (0.69, 1.12) e
Hyperlipidemia 0.87 (0.69, 1.11) 0.99 (0.77, 1.28) e
Smoking 1.20 (0.96, 1.49) 1.26 (0.99, 1.60) e
Chronic renal failure (Cr >2 mg/dL) 1.83 (1.43, 2.34)** 2.02 (1.51, 2.70)** 1.79 (1.39, 2.30)**
Coronary artery disease 1.08 (0.87, 1.34) 0.91 (0.73, 1.14) e
Cerebrovascular disease 0.88 (0.68, 1.13) 0.87 (0.67, 1.13) e
Rutherford class 6 2.21 (1.75, 2.79)** 2.12 (1.64, 2.74)** 2.07 (1.62, 2.64)**
Three-vessel below-the-knee disease 1.11 (0.89, 1.39) 1.07 (0.85, 1.36) e
Arterial calciﬁcation 1.23 (0.97, 1.55) 0.85 (0.65, 1.11) e
No below-the-ankle runoff 1.41 (1.12, 1.79)** 1.38 (1.08, 1.77)* 1.33 (1.05, 1.69)*
Note. Data are HR and 95% CI for MALE. In Multivariate model 1, all the explanatory variables were entered, whereas in multivariate model
2, the variables entered were selected by stepwise method. CLI ¼ critical limb ischemia; CRP ¼ C-reactive protein; EVT ¼ endovascular
therapy; MALE ¼ major adverse limb event.*p < .05, **p < .01.
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beneﬁt from direct EVT. Also, angiosome-based revascular-
ization needs to be validated in the technically challenging
setting of infrapopliteal reconstruction. This study however
provides initial evidence to facilitate decision making for
contemporary endovascular reconstruction in patients with
CLI due to isolated pure infrapopliteal lesions. Further
investigation focused on the role, advantages and draw-
backs of angiosome-based revascularization is needed.CONCLUSION
Limb prognosis was equivalent for direct and indirect
endovascular revascularization except in the presence of acombination of DM and wound infection, when indirect
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